From: GnRH and LHRgene variants predict adverse outcome in premenopausal breast cancer patients
 |  | LHR insLQ |  | GnRH 16Ser |  | ||
---|---|---|---|---|---|---|---|
Feature | Number (percent) | Non-carriers (percent) | Carriers (percent)a | P valuea | Non-carriers (percent) | Carriers (percent) | P valuea |
Breast cancer cases | 278 (100) | 147 (53) | 131 (47) | Â | 157 (56) | 121 (44) | Â |
Age in years | Â | Â | Â | 0.18 | Â | Â | 0.56 |
   <35 | 19 (7) | 12 | 7 |  | 9 | 10 |  |
   35–39 | 35 (12) | 13 | 22 |  | 17 | 18 |  |
   40–49 | 167 (60) | 93 | 74 |  | 99 | 68 |  |
   50–59 | 57 (21) | 29 | 28 |  | 32 | 25 |  |
Node status | Â | Â | Â | 0.78 | Â | Â | 0.001 b |
   Negative | 134 (48) | 72 | 62 |  | 89 | 45 |  |
   Positive | 144 (52) | 75 | 69 |  | 68 | 76 |  |
Histological grade c | Â | Â | Â | 0.04 | Â | Â | 0.15 |
   Well/mod | 66 (24) | 44 | 22 |  | 41 | 25 |  |
   unknown | 59 (21) | 28 | 31 |  | 27 | 32 |  |
   Poor | 153 (55) | 75 | 78 |  | 89 | 64 |  |
Tumor size d | Â | Â | Â | 0.58 | Â | Â | 0.30 |
   ≤2 cm | 113 (41) | 62 | 51 |  | 68 | 45 |  |
   >2 cm | 165 (59) | 85 | 80 |  | 89 | 76 |  |
Estrogen receptor status c,e | Â | Â | Â | 0.095 | Â | Â | 0.29 |
   Negative | 78 (28) | 35 | 43 |  | 48 | 30 |  |
   Positive | 200 (72) | 112 | 88 |  | 109 | 91 |  |
Progesterone receptor status c,e | Â | Â | Â | 0.15 | Â | Â | 0.54f |
   Negative | 70 (25) | 32 | 38 |  | 42 | 28 |  |
   Positive | 199 (72) | 111 | 88 |  | 111 | 88 |  |
HER2 amplified c | Â | Â | Â | 0.68 | Â | Â | 0.85 |
   Yes | 55 (20) | 28 | 27 |  | 30 | 25 |  |
   No | 202 (73) | 106 | 96 |  | 114 | 88 |  |
Adjuvant therapy | Â | Â | Â | 0.54 | Â | Â | 0.09 |
   No | 158 (57) | 88 | 70 |  | 96 | 62 |  |
   Hormonal | 4 (1) | 1 | 3 |  | 1 | 3 |  |
   Chemotherapy | 110 (40) | 55 | 55 |  | 55 | 55 |  |
   Combined | 6 (2) | 3 | 3 |  | 5 | 1 |  |